Top

22-04-2024 | Cytostatic Therapy | Letter to the Editor

Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients

Author: Kadri Altundag

Excerpt

To The Editor, …

De Moura A, Loirat D, Vaillant S, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at institut curie hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024. https://doi.org/10.1007/s12282-024-01565-7. (Epub ahead of print).CrossRefPubMed

Bardia A, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41.CrossRefPubMed

Title: Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients
Author: Kadri Altundag
Publication date: 22-04-2024
Publisher: Springer Nature Singapore
Keywords: Cytostatic Therapy
Breast Cancer
Breast Cancer
Published in: Breast Cancer
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-024-01587-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer